480 related articles for article (PubMed ID: 35151397)
1. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2022 Feb; 399(10325):665-676. PubMed ID: 35151397
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
Hirsch C; Park YS; Piechotta V; Chai KL; Estcourt LJ; Monsef I; Salomon S; Wood EM; So-Osman C; McQuilten Z; Spinner CD; Malin JJ; Stegemann M; Skoetz N; Kreuzberger N
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD014945. PubMed ID: 35713300
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343
[TBL] [Abstract][Full Text] [Related]
4. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
O'Brien MP; Forleo-Neto E; Sarkar N; Isa F; Hou P; Chan KC; Musser BJ; Bar KJ; Barnabas RV; Barouch DH; Cohen MS; Hurt CB; Burwen DR; Marovich MA; Brown ER; Heirman I; Davis JD; Turner KC; Ramesh D; Mahmood A; Hooper AT; Hamilton JD; Kim Y; Purcell LA; Baum A; Kyratsous CA; Krainson J; Perez-Perez R; Mohseni R; Kowal B; DiCioccio AT; Geba GP; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD; Weinreich DM;
JAMA; 2022 Feb; 327(5):432-441. PubMed ID: 35029629
[TBL] [Abstract][Full Text] [Related]
5. Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.
Portal-Celhay C; Forleo-Neto E; Eagan W; Musser BJ; Davis JD; Turner KC; Norton T; Hooper AT; Hamilton JD; Pan C; Mahmood A; Baum A; Kyratsous CA; Kim Y; Parrino J; Kampman W; Roque-Guerrero L; Stoici R; Fatakia A; Soo Y; Geba GP; Kowal B; DiCioccio AT; Stahl N; Lipsich L; Braunstein N; Herman GA; Yancopoulos GD; Weinreich DM;
JAMA Netw Open; 2022 Aug; 5(8):e2225411. PubMed ID: 35969402
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial.
Huang DT; McCreary EK; Bariola JR; Minnier TE; Wadas RJ; Shovel JA; Albin D; Marroquin OC; Kip KE; Collins K; Schmidhofer M; Wisniewski MK; Nace DA; Sullivan C; Axe M; Meyers R; Weissman A; Garrard W; Peck-Palmer OM; Wells A; Bart RD; Yang A; Berry LR; Berry S; Crawford AM; McGlothlin A; Khadem T; Linstrum K; Montgomery SK; Ricketts D; Kennedy JN; Pidro CJ; Nakayama A; Zapf RL; Kip PL; Haidar G; Snyder GM; McVerry BJ; Yealy DM; Angus DC; Seymour CW
JAMA Netw Open; 2022 Jul; 5(7):e2220957. PubMed ID: 35834252
[TBL] [Abstract][Full Text] [Related]
7. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2021 Feb; 397(10274):605-612. PubMed ID: 33545096
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
Herman GA; O'Brien MP; Forleo-Neto E; Sarkar N; Isa F; Hou P; Chan KC; Bar KJ; Barnabas RV; Barouch DH; Cohen MS; Hurt CB; Burwen DR; Marovich MA; Musser BJ; Davis JD; Turner KC; Mahmood A; Hooper AT; Hamilton JD; Parrino J; Subramaniam D; Baum A; Kyratsous CA; DiCioccio AT; Stahl N; Braunstein N; Yancopoulos GD; Weinreich DM;
Lancet Infect Dis; 2022 Oct; 22(10):1444-1454. PubMed ID: 35803290
[TBL] [Abstract][Full Text] [Related]
9. Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19.
McCreary EK; Bariola JR; Wadas RJ; Shovel JA; Wisniewski MK; Adam M; Albin D; Minnier T; Schmidhofer M; Meyers R; Marroquin OC; Collins K; Garrard W; Berry LR; Berry S; Crawford AM; McGlothlin A; Linstrum K; Nakayama A; Montgomery SK; Snyder GM; Yealy DM; Angus DC; Kip PL; Seymour CW; Huang DT; Kip KE
JAMA Netw Open; 2022 Apr; 5(4):e226920. PubMed ID: 35412625
[TBL] [Abstract][Full Text] [Related]
10. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet Respir Med; 2021 Dec; 9(12):1419-1426. PubMed ID: 34672950
[TBL] [Abstract][Full Text] [Related]
11. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
RECOVERY Collaborative Group
Lancet; 2022 Jul; 400(10349):359-368. PubMed ID: 35908569
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet Child Adolesc Health; 2024 Mar; 8(3):190-200. PubMed ID: 38272046
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2021 May; 397(10285):1637-1645. PubMed ID: 33933206
[TBL] [Abstract][Full Text] [Related]
14. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
15. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2021 May; 397(10289):2049-2059. PubMed ID: 34000257
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet Diabetes Endocrinol; 2023 Dec; 11(12):905-914. PubMed ID: 37865101
[TBL] [Abstract][Full Text] [Related]
17. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
Butler CC; Yu LM; Dorward J; Gbinigie O; Hayward G; Saville BR; Van Hecke O; Berry N; Detry MA; Saunders C; Fitzgerald M; Harris V; Djukanovic R; Gadola S; Kirkpatrick J; de Lusignan S; Ogburn E; Evans PH; Thomas NPB; Patel MG; Hobbs FDR;
Lancet Respir Med; 2021 Sep; 9(9):1010-1020. PubMed ID: 34329624
[TBL] [Abstract][Full Text] [Related]
18. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2022 Jan; 399(10320):143-151. PubMed ID: 34800427
[TBL] [Abstract][Full Text] [Related]
19. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2020 Oct; 396(10259):1345-1352. PubMed ID: 33031764
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting.
Jovanoski N; Kuznik A; Becker U; Hussein M; Briggs A
J Manag Care Spec Pharm; 2022 May; 28(5):555-565. PubMed ID: 35238626
[No Abstract] [Full Text] [Related]
[Next] [New Search]
